{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T15:38:44Z","timestamp":1773502724062,"version":"3.50.1"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T00:00:00Z","timestamp":1712188800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Vet. Sci."],"abstract":"<jats:p>Rivaroxaban, a specific factor Xa inhibitor and commonly utilized anticoagulant, has been known to cause hepatotoxicity and liver failure in humans. Although rivaroxaban is frequently used in veterinary medicine, hepatotoxicity has not been previously reported in dogs. The current case report describes a dog that developed severe hepatopathy following rivaroxaban administration for a large right pulmonary artery thrombus. An estimated 6-year-old spayed female mixed-breed dog developed anorexia and lethargy 9\u2009days after rivaroxaban administration began. Subsequent labwork revealed severe hepatocellular hepatopathy, and rivaroxaban was discontinued. Additional diagnostics did not reveal an underlying etiology, although hepatic cytology could be consistent with a toxic injury. The hepatopathy and clinical signs improved after rivaroxaban was discontinued. The time to onset, type of hepatopathy, and time to resolution were all similar to those reported for human cases. This case provides precedence to advocate for improved and closer monitoring of dogs receiving factor Xa inhibitors. In cases of suspected hepatotoxicity with no other identifiable cause, a risk\u2013benefit analysis should be performed, and discontinuation of rivaroxaban administration or alternative anticoagulant medications should be considered.<\/jats:p>","DOI":"10.3389\/fvets.2024.1364677","type":"journal-article","created":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T05:08:55Z","timestamp":1712207335000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case report: Severe hepatopathy following rivaroxaban administration in a dog"],"prefix":"10.3389","volume":"11","author":[{"given":"Allison P.","family":"Mosichuk","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Candace","family":"Wimbish","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristen","family":"Poplawski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Birkenheuer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karyn","family":"Harrell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kursten V.","family":"Pierce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,4,4]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.tvjl.2017.03.006","article-title":"Anticoagulant activity of oral rivaroxaban in healthy dogs","volume":"223","author":"Conversy","year":"2017","journal-title":"Vet J"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"636","DOI":"10.2174\/1389200218666170518165443","article-title":"Rivaroxaban\u2014metabolism, pharmacologic properties and drug interactions","volume":"18","author":"Kvasnicka","year":"2017","journal-title":"Curr Drug Metab"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1161\/ATVBAHA.107.139402","article-title":"Oral, direct factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases","volume":"27","author":"Turpie","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.thromres.2010.09.008","article-title":"The mechanism of action of rivaroxaban--an oral, direct factor Xa inhibitor--compared with other anticoagulants","volume":"127","author":"Samama","year":"2011","journal-title":"Thromb Res"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1177\/1753944715605011","article-title":"Factor Xa inhibitors: a novel therapeutic class for the treatment of nonvalvular atrial fibrillation","volume":"10","author":"McCarty","year":"2016","journal-title":"Ther Adv Cardiovasc Dis"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s40264-015-0317-5","article-title":"Hepatotoxicity of new Oral anticoagulants (NOACs)","volume":"38","author":"Liakoni","year":"2015","journal-title":"Drug Saf"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1097\/MEG.0000000000001030","article-title":"Rivaroxaban-induced hepatotoxicity: review of the literature and report of new cases","volume":"30","author":"Licata","year":"2018","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1136\/heartjnl-2013-305288","article-title":"Risk of drug-induced liver injury with the new oral anticoagulants: systematic review and meta-analysis","volume":"100","author":"Caldeira","year":"2014","journal-title":"Heart"},{"key":"ref9","year":"2012"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/vec.12797","article-title":"Consensus on the rational use of Antithrombotics in veterinary critical care (CURATIVE): domain 1-defining populations at risk","volume":"29","author":"deLaforcade","year":"2019","journal-title":"J Vet Emerg Crit Care"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/vec.13204","article-title":"2022 update of the consensus on the rational use of Antithrombotics and Thrombolytics in veterinary critical care (CURATIVE) domain 1-defining populations at risk","volume":"32","author":"deLaforcade","year":"2022","journal-title":"J Vet Emerg Crit Care"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1111\/vec.12791","article-title":"Consensus on the rational use of Antithrombotics in veterinary critical care (CURATIVE): domain 2-defining rational therapeutic usage","volume":"29","author":"Goggs","year":"2019","journal-title":"J Vet Emerg Crit Care"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1111\/vec.12795","article-title":"Consensus on the rational use of Antithrombotics in veterinary critical care (CURATIVE): domain 3-defining antithrombotic protocols","volume":"29","author":"Blais","year":"2019","journal-title":"J Vet Emerg Crit Care"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1111\/vec.12794","article-title":"Consensus on the rational use of Antithrombotics in veterinary critical care (CURATIVE): domain 4-refining and monitoring antithrombotic therapies","volume":"29","author":"Sharp","year":"2019","journal-title":"J Vet Emerg Crit Care"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1002\/vms3.161","article-title":"A prospective evaluation of rivaroxaban on haemostatic parameters in apparently healthy dogs","volume":"5","author":"Evans","year":"2019","journal-title":"Vet Med Sci"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1111\/vec.13199","article-title":"Clinical features and posttreatment monitoring of dogs administered rivaroxaban (2018-2020): 19 cases","volume":"32","author":"Tracy","year":"2022","journal-title":"J Vet Emerg Crit Care"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.jhep.2014.03.026","article-title":"Rivaroxaban postmarketing risk of liver injury","volume":"61","author":"Russmann","year":"2014","journal-title":"J Hepatol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1111\/liv.14559","article-title":"Liver injury caused by oral anticoagulants: a population-based retrospective cohort study","volume":"40","author":"Bj\u00f6rnsson","year":"2020","journal-title":"Liver Int"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1111\/bcp.12611","article-title":"Liver injury with novel oral anticoagulants: assessing post-marketing reports in the US Food and Drug Administration adverse event reporting system","volume":"80","author":"Raschi","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1007\/s00277-018-3364-z","article-title":"Drug-induced liver failure due to rivaroxaban","volume":"97","author":"Peverelle","year":"2018","journal-title":"Ann Hematol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"243","DOI":"10.2165\/11586600-000000000-00000","article-title":"Evaluation of drug-induced serious hepatotoxicity (eDISH): application of this data organization approach to phase III clinical trials of rivaroxaban after total hip or knee replacement surgery","volume":"34","author":"Watkins","year":"2011","journal-title":"Drug Saf"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1097\/MBC.0000000000000363","article-title":"Use of apixaban after development of suspected rivaroxaban-induced hepatic steatosis; a case report","volume":"26","author":"Anastasia","year":"2015","journal-title":"Blood Coagul Fibrinolysis"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.ijcard.2015.04.248","article-title":"Rivaroxaban-induced liver injury: results from a venous thromboembolism registry","volume":"191","author":"Lambert","year":"2015","journal-title":"Int J Cardiol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1001\/jamainternmed.2014.3912","article-title":"Symptomatic hepatocellular liver injury with hyperbilirubinemia in two patients treated with rivaroxaban","volume":"174","author":"Liakoni","year":"2014","journal-title":"JAMA Intern Med"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1007\/s10620-014-3504-9","article-title":"Severe drug-induced skin and liver injury from rivaroxaban","volume":"60","author":"Barrett","year":"2015","journal-title":"Dig Dis Sci"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1136\/heartjnl-2016-310586","article-title":"Prospective study of oral anticoagulants and risk of liver injury in patients with atrial fibrillation","volume":"103","author":"Alonso","year":"2017","journal-title":"Heart"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1007\/s00228-020-03084-8","article-title":"Liver injury during rivaroxaban treatment in a patient with AL amyloidosis","volume":"77","author":"Marrinan","year":"2021","journal-title":"Eur J Clin Pharmacol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"003685042110701","DOI":"10.1177\/00368504211070183","article-title":"Prevalence of polypharmacy and risk of potential drug-drug interactions among hospitalized patients with emphasis on the pharmacokinetics","volume":"105","author":"Georgiev","year":"2022","journal-title":"Sci Prog"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"15727","DOI":"10.1038\/s41598-020-72950-3","article-title":"Prospective observational study of the use of omeprazole and maropitant citrate in veterinary specialist care","volume":"10","author":"McCormack","year":"2020","journal-title":"Sci Rep"}],"container-title":["Frontiers in Veterinary Science"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fvets.2024.1364677\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T05:08:57Z","timestamp":1712207337000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fvets.2024.1364677\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,4]]},"references-count":29,"alternative-id":["10.3389\/fvets.2024.1364677"],"URL":"https:\/\/doi.org\/10.3389\/fvets.2024.1364677","relation":{},"ISSN":["2297-1769"],"issn-type":[{"value":"2297-1769","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,4]]},"article-number":"1364677"}}